Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
enGene Holdings Inc. (ENGN)
USD1.95
+0.06 (+2.90%)
CA NASDAQ Healthcare Biotechnology
Address
7171 Rue Frederick Banting H4S 1Z9
Saint-Laurent, CA
Saint-Laurent, CA
CEO
Ronald H. W. Cooper
Website
engene.com
IPO
2022-02-01
CIK 1980845 ISIN CA29286X1015
Also trades on
NASDAQ Capital Market · ENGN (USD)
NASDAQ Capital Market · ENGNW (USD)
Description
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.95
+0.06 (+2.90%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
-0.28
Float Shares
21.52M
Free Float %
42.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +9.26% | +5.99% | +2.91% | -75.28% | -79.00% | -80.40% | -46.53% | -91.15% | -91.15% | -91.15% | -91.15% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Hold
Price Targets & DCF
Current price
1.95
Low
2.00
+2.6%
Consensus
7.00
+259.0%
Median
3.00
+53.8%
High
28.00
+1,335.9%
DCF (Unlevered)
0.28
-85.8%
DCF (Levered)
0.36
-81.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
27% Bullish
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 1 | -2 |
| Buy | 2 | -5 |
| Hold | 8 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 5 |
2.80
+43.6%
|
| Last Year | 10 |
13.70
+602.6%
|
| All Time | 12 |
14.33
+634.9%
|
Quality scores
Altman Z-Score
-0.64
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-56.9% Q2'26: -15.7% (vs Q2'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-2,008.9% Q2'26: +0.0% (vs Q2'25)
-
Share dilution Biotechnology: -3.4%+14.5% Q2'26: +36.7% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.28× Q2'26: 0.06× (vs Q2'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Oct 2024 actual |
Oct 2025 actual |
Oct 2026 8 Rev. Ana. 7 EPS Ana. |
Oct 2027 5 Rev. Ana. 7 EPS Ana. |
Oct 2028 1 Rev. Ana. 3 EPS Ana. |
Oct 2029 2 Rev. Ana. 4 EPS Ana. |
Oct 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
4.78M
1.84M – 7.72M
|
7.57M
2.92M – 12.23M
+58.3% YoY
|
53.35M
20.55M – 86.15M
+604.4% YoY
|
131.40M
50.62M – 212.18M
+146.3% YoY
|
216.36M
83.35M – 349.37M
+64.7% YoY
|
| EBITDA |
-52.04M
|
-113.80M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-52.36M
|
-114.31M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-55.14M
est: -65.17M (+15.4%)
|
-117.30M
est: -107.47M (-9.1%)
|
-100.57M
-106.05M – -92.61M
+6.4% YoY
|
-100.40M
-126.70M – -76.24M
+0.2% YoY
|
-78.63M
-141.46M – -15.79M
+21.7% YoY
|
-51.19M
-92.11M – -10.28M
+34.9% YoY
|
-28.55M
-51.37M – -5.73M
+44.2% YoY
|
| SGA |
23.98M
|
28.69M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.46
est: -1.46 (+0.0%)
|
-2.29
est: -2.10 (-8.9%)
|
-1.97
-2.07 – -1.81
+6.4% YoY
|
-1.96
-2.48 – -1.49
+0.2% YoY
|
-1.54
-2.77 – -0.31
+21.7% YoY
|
-1.00
-1.80 – -0.20
+34.9% YoY
|
-0.56
-1.00 – -0.11
+44.2% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-14 | UBS | Neutral | Neutral | Maintain |
| 2026-05-08 | Piper Sandler | Overweight | Neutral | Downgrade |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-06-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-06-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-06-10 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-06-09 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-06-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-06-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-06-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-06-03 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-06-02 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-06-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
59
Total invested
380.01M
Insider transactions (90d)
0
Beneficial owners (>5%)
14
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abigail P. Johnson | 26.35M | 2.22% | — | — | 26.35M | — | IN | Delaware | 2024-11-12 | ↗ |
| 2 | 98-0557567 | 6.40M | 5.10% | 6.40M | — | 6.40M | — | IA, HC | Bermuda | 2024-11-07 | ↗ |
| 3 | Adage Capital Management, L.P. | 2.33M | 5.27% | — | 2.33M | — | — | IA, PN | Delaware | 2024-11-12 | ↗ |
| 4 | Phillip Gross | 2.33M | 5.27% | — | 2.33M | — | — | HC, IN | Delaware | 2024-11-12 | ↗ |
| 5 | Robert Atchinson | 2.33M | 5.27% | — | 2.33M | — | — | HC, IN | Delaware | 2024-11-12 | ↗ |
| 6 | MONEY CONCEPTS CAPITAL CORP | 2.02M | 45.90% | — | — | 2.02M | — | IA | FLORIDA, USA | 2024-11-14 | ↗ |
| 7 | FIL Limited | 974.7K | 5.78% | 281.6K | — | 974.7K | — | FI | Bermuda | 2024-11-12 | ↗ |
| 8 | 25-1435979 | 403.2K | 6.50% | 396.7K | — | 336.3K | 66.9K | HC | Pennsylvania | 2024-11-14 | ↗ |
| 9 | 22-1146430 | 395.3K | 6.38% | 392.3K | — | 332.3K | 62.9K | BK | Pennsylvania | 2024-11-14 | ↗ |
| 10 | (1) BlackRock, Inc. | 40.0K | 33.30% | 40.0K | — | 40.0K | — | HC | Delaware | 2024-12-06 | ↗ |
| 11 | PNC Delaware Trust Company 81-0581990 | 4.1K | 0.07% | 4.1K | — | 3.6K | 527.00 | BK | Pennsylvania | 2024-11-14 | ↗ |
| 12 | PNC Investments LLC 42-1604685 | 3.5K | 0.06% | — | — | — | 3.5K | BD | Pennsylvania | 2024-11-14 | ↗ |
| 13 | PNC Ohio Trust Company 81-0991531 | 320.00 | 0.01% | 320.00 | — | 320.00 | — | BK | Pennsylvania | 2024-11-14 | ↗ |
| 14 | FMR LLC | — | 0.00% | — | — | — | — | HC | Delaware | 2024-11-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
59
+2 vs prev Q
New positions
12
Closed positions
10
Increased
34
Reduced
14
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 210.0K +210.0K (+100.0%) | 1.90B +1.9B (+100.0%) | 0.41% +0.409 pp | 0.56% +0.560 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 2 | FCPM III SERVICES B.V. | 9.63M +— (+0.0%) | 86.98M +21.2M (+32.2%) | 18.78% -0.076 pp | 11.40% -1.746 pp | USD8.97 +0.7% | 9 qtrs — |
| 3 | PERCEPTIVE ADVISORS LLC | 5.87M +3.8M (+179.8%) | 53.00M +38.7M (+270.0%) | 11.44% +7.335 pp | 0.94% +0.531 pp | USD8.24 +9.6% | 2 qtrs — |
| 4 | VR ADVISER, LLC | 4.77M -275.0K (-5.4%) | 43.09M +8.6M (+25.0%) | 9.33% -0.542 pp | 2.13% +0.188 pp | USD11.97 -24.6% | 8 qtrs — |
| 5 | DEEP TRACK CAPITAL, LP | 4.38M +2.1M (+95.5%) | 39.53M +24.2M (+158.5%) | 8.56% +4.181 pp | 0.70% +0.278 pp | USD10.40 -13.2% | 8 qtrs — |
| 6 | CORMORANT ASSET MANAGEMENT, LP | 4.00M +1.7M (+72.1%) | 36.12M +20.2M (+127.6%) | 7.82% +3.277 pp | 1.67% +0.575 pp | USD10.21 -11.6% | 8 qtrs — |
| 7 | BLUE OWL CAPITAL HOLDINGS LP | 3.36M +82.8K (+2.5%) | 30.35M +8.0M (+35.6%) | 6.55% +0.136 pp | 2.27% -4.680 pp | USD10.38 -13.0% | 9 qtrs — |
| 8 | SIREN, L.L.C. | 3.34M +3.3M (+100.0%) | 30.13M +30.1M (+100.0%) | 6.53% +6.526 pp | 0.90% +0.899 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 9 | BRAIDWELL LP | 3.13M +865.0K (+38.2%) | 28.28M +12.8M (+82.7%) | 6.10% +1.668 pp | 0.90% +0.445 pp | USD7.44 +21.4% | 2 qtrs — |
| 10 | NEXTECH INVEST, LTD. | 2.12M +2.1M (+100.0%) | 19.19M +19.2M (+100.0%) | 4.16% +4.157 pp | 1.86% +1.855 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 11 | JANUS HENDERSON GROUP PLC | 1.90M +1.9M (+100.0%) | 17.11M +17.1M (+100.0%) | 3.72% +3.717 pp | 0.01% +0.008 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 12 | BIOIMPACT CAPITAL LLC | 1.84M +1.3M (+247.1%) | 16.62M +13.0M (+359.0%) | 3.60% +2.563 pp | 1.90% +1.309 pp | USD8.40 +7.5% | 2 qtrs — |
| 13 | MILLENNIUM MANAGEMENT LLC | 1.50M +1.5M (+7,214.0%) | 13.54M +13.4M (+9,569.9%) | 2.92% +2.883 pp | 0.01% +0.006 pp | USD8.97 +0.7% | 3 qtrs — |
| 14 | KYNAM CAPITAL MANAGEMENT, LP | 1.49M -3.5M (-70.1%) | 13.48M -20.6M (-60.5%) | 2.92% -6.853 pp | 0.86% -1.679 pp | USD6.63 +36.2% | 6 qtrs — |
| 15 | FRANKLIN RESOURCES INC | 1.39M +350.0K (+33.7%) | 12.53M +5.4M (+76.8%) | 2.71% +0.674 pp | 0.00% +0.001 pp | USD12.39 -27.1% | 8 qtrs — |
| 16 | POLAR CAPITAL HOLDINGS PLC | 1.14M +1.1M (+100.0%) | 10.32M +10.3M (+100.0%) | 2.23% +2.228 pp | 0.04% +0.040 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 17 | VESTAL POINT CAPITAL, LP | 1.06M +685.0K (+185.1%) | 9.53M +7.0M (+277.0%) | 2.06% +1.332 pp | 0.32% +0.210 pp | USD8.20 +10.1% | 5 qtrs — |
| 18 | EVENTIDE ASSET MANAGEMENT, LLC | 950.0K +950.0K (+100.0%) | 8.58M +8.6M (+100.0%) | 1.86% +1.858 pp | 0.13% +0.134 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 19 | OMEGA FUND MANAGEMENT, LLC | 876.4K +350.0K (+66.5%) | 7.91M +4.3M (+120.1%) | 1.71% +0.684 pp | 2.76% +1.145 pp | USD9.15 -1.3% | 9 qtrs — |
| 20 | SR ONE CAPITAL MANAGEMENT, LP | 747.8K +— (+0.0%) | 6.75M +1.6M (+32.2%) | 1.46% -0.006 pp | 0.96% +0.217 pp | USD8.24 +9.6% | 7 qtrs — |
| 21 | MORGAN STANLEY | 718.5K +283.2K (+65.1%) | 6.49M +3.5M (+118.2%) | 1.40% +0.549 pp | 0.00% +0.000 pp | USD7.61 +18.7% | 9 qtrs — |
| 22 | AFFINITY ASSET ADVISORS, LLC | 643.4K +566.4K (+735.5%) | 5.81M +5.3M (+1,004.7%) | 1.26% +1.108 pp | 0.33% +0.285 pp | USD8.38 +7.8% | 3 qtrs — |
| 23 | POINT72 ASSET MANAGEMENT, L.P. | 561.8K -646.6K (-53.5%) | 5.07M -3.2M (-38.5%) | 1.10% -1.266 pp | 0.01% -0.008 pp | USD6.96 +29.7% | 8 qtrs — |
| 24 | EVERSEPT PARTNERS, LP | 455.8K +455.8K (+100.0%) | 4.12M +4.1M (+100.0%) | 0.89% +0.889 pp | 0.21% +0.207 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 25 | PRIVIUM FUND MANAGEMENT B.V. | 352.1K +352.1K (+100.0%) | 3.18M +3.2M (+100.0%) | 0.69% +0.686 pp | 0.59% +0.585 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 26 | MARSHALL WACE, LLP | 343.9K +— (+0.0%) | 3.11M +756.6K (+32.2%) | 0.67% -0.003 pp | 0.00% +0.000 pp | USD16.89 -46.5% | 8 qtrs — |
| 27 | ADAR1 CAPITAL MANAGEMENT, LLC | 303.7K +303.7K (+100.0%) | 2.74M +2.7M (+100.0%) | 0.59% +0.592 pp | 0.20% +0.201 pp | USD9.03 +0.0% | 7 qtrs — |
| 28 | MONASHEE INVESTMENT MANAGEMENT LLC | 295.0K +295.0K (+100.0%) | 2.66M +2.7M (+100.0%) | 0.58% +0.575 pp | 1.50% +1.501 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 29 | WOODLINE PARTNERS LP | 250.0K +250.0K (+100.0%) | 2.26M +2.3M (+100.0%) | 0.49% +0.487 pp | 0.01% +0.009 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 30 | DAFNA CAPITAL MANAGEMENT LLC | 163.6K +163.6K (+100.0%) | 1.48M +1.5M (+100.0%) | 0.32% +0.320 pp | 0.34% +0.343 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 31 | TWO SIGMA INVESTMENTS, LP | 161.5K +161.5K (+100.0%) | 1.46M +1.5M (+100.0%) | 0.31% +0.315 pp | 0.00% +0.002 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 32 | GOLDMAN SACHS GROUP INC | 147.9K +287.0 (+0.2%) | 1.34M +327.3K (+32.5%) | 0.29% -0.001 pp | 0.00% +0.000 pp | USD6.65 +35.8% | 5 qtrs — |
| 33 | KENNEDY CAPITAL MANAGEMENT LLC | 76.8K +76.8K (+100.0%) | 693.2K +693.2K (+100.0%) | 0.15% +0.150 pp | 0.01% +0.015 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 34 | HRT FINANCIAL LP | 64.4K +64.4K (+100.0%) | 581.0K +581.0K (+100.0%) | 0.13% +0.126 pp | 0.00% +0.002 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 35 | JANE STREET GROUP, LLC | 56.5K +56.5K (+100.0%) | 509.8K +509.8K (+100.0%) | 0.11% +0.110 pp | 0.00% +0.000 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 36 | QUADRATURE CAPITAL LTD | 48.6K +48.6K (+100.0%) | 438.7K +438.7K (+100.0%) | 0.09% +0.095 pp | 0.00% +0.005 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 37 | BNP PARIBAS ARBITRAGE, SNC | 35.9K +35.9K (+100.0%) | 324.0K +324.0K (+100.0%) | 0.07% +0.070 pp | 0.00% +0.000 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 38 | VIRTUS INVESTMENT ADVISERS, INC. | 31.4K +31.4K (+100.0%) | 283.9K +283.9K (+100.0%) | 0.06% +0.061 pp | 0.08% +0.077 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 39 | NORTHERN TRUST CORP | 30.1K -210.0 (-0.7%) | 271.7K +64.8K (+31.3%) | 0.06% 0.000 pp | 0.00% +0.000 pp | USD6.60 +36.8% | 6 qtrs — |
| 40 | GEODE CAPITAL MANAGEMENT, LLC | 29.0K +— (+0.0%) | 262.0K +63.8K (+32.2%) | 0.06% 0.000 pp | 0.00% +0.000 pp | USD13.28 -32.0% | 8 qtrs — |
| 41 | CITADEL ADVISORS LLC | 25.4K -33.0K (-56.5%) | 229.2K -169.5K (-42.5%) | 0.05% -0.065 pp | 0.00% +0.000 pp | USD5.57 +62.1% | 3 qtrs — |
| 42 | PALE FIRE CAPITAL SE | 24.0K +6.8K (+39.1%) | 216.8K +98.9K (+83.9%) | 0.05% +0.013 pp | 0.01% +0.002 pp | USD7.09 +27.4% | 5 qtrs — |
| 43 | AMERICAN CENTURY COMPANIES INC | 24.0K +24.0K (+100.0%) | 216.5K +216.5K (+100.0%) | 0.05% +0.047 pp | 0.00% +0.000 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 44 | XTX TOPCO LTD | 23.9K +23.9K (+100.0%) | 216.0K +216.0K (+100.0%) | 0.05% +0.047 pp | 0.01% +0.006 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 45 | RENAISSANCE TECHNOLOGIES LLC | 20.8K +20.8K (+100.0%) | 187.7K +187.7K (+100.0%) | 0.04% +0.041 pp | 0.00% +0.000 pp | USD9.03 +0.0% | 3 qtrs — |
| 46 | RAYMOND JAMES FINANCIAL INC | 20.0K +10.0K (+99.6%) | 180.2K +111.9K (+163.9%) | 0.04% +0.020 pp | 0.00% +0.000 pp | USD7.60 +18.8% | 3 qtrs — |
| 47 | TWO SIGMA ADVISERS, LP | 17.3K +17.3K (+100.0%) | 156.2K +156.2K (+100.0%) | 0.03% +0.034 pp | 0.00% +0.000 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 48 | SCHONFELD STRATEGIC ADVISORS LLC | 16.6K -8.4K (-33.6%) | 150.3K -20.9K (-12.2%) | 0.03% -0.017 pp | 0.00% 0.000 pp | USD7.46 +21.0% | 8 qtrs — |
| 49 | JUMP FINANCIAL, LLC | 13.4K +13.4K (+100.0%) | 121.0K +121.0K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.002 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 50 | WELLS FARGO & COMPANY/MN | 11.2K -6.7K (-37.4%) | 101.3K -21.0K (-17.2%) | 0.02% -0.013 pp | 0.00% +0.000 pp | USD6.62 +36.4% | 7 qtrs — |
| 51 | PFS PARTNERS, LLC | 11.0K +2.0K (+22.2%) | 99.3K +37.9K (+61.6%) | 0.02% +0.004 pp | 0.05% +0.016 pp | USD7.23 +24.9% | 2 qtrs — |
| 52 | ROYAL BANK OF CANADA | 7.9K +— (+0.0%) | 71.0K +17.0K (+31.5%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD9.23 -2.2% | 9 qtrs — |
| 53 | JPMORGAN CHASE & CO | 2.6K +2.6K (+100.0%) | 23.6K +23.6K (+100.0%) | 0.01% +0.005 pp | 0.00% +0.000 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 54 | CITIGROUP INC | 1.7K +1.7K (+168,700.0%) | 15.2K +15.2K (+217,657.1%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD9.03 +0.0% | 2 qtrs — |
| 55 | UBS GROUP AG | 1.6K +1.6K (+100.0%) | 14.4K +14.4K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD9.03 +0.0% | 1 qtrs NEW |
| 56 | MAI CAPITAL MANAGEMENT | 776.00 +— (+0.0%) | 7.0K +1.7K (+32.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.43 +40.4% | 5 qtrs — |
| 57 | SBI SECURITIES CO., LTD. | 28.00 -3.0 (-9.7%) | 253.00 +41.0 (+19.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.61 +36.6% | 5 qtrs — |
| 58 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | — -1.2M (-100.0%) | — -7.9M (-100.0%) | 0.00% -2.265 pp | 0.00% -0.237 pp | USD— | 2 qtrs SOLD |
| 59 | BANK OF AMERICA CORP /DE/ | — -647.2K (-100.0%) | — -4.4M (-100.0%) | 0.00% -1.267 pp | 0.00% 0.000 pp | USD— | 4 qtrs SOLD |
| 60 | HUDSON BAY CAPITAL MANAGEMENT LP | — -11.1K (-100.0%) | — -75.6K (-100.0%) | 0.00% -0.022 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 61 | SPHERA FUNDS MANAGEMENT LTD. | — -504.4K (-100.0%) | — -3.4M (-100.0%) | 0.00% -0.987 pp | 0.00% -0.727 pp | USD— | 5 qtrs SOLD |
| 62 | TORONTO DOMINION BANK | — -10.0K (-100.0%) | — -68.3K (-100.0%) | 0.00% -0.020 pp | 0.00% 0.000 pp | USD— | 5 qtrs SOLD |
| 63 | ADAGE CAPITAL PARTNERS GP, L.L.C. | — -1.0M (-100.0%) | — -6.8M (-100.0%) | 0.00% -1.957 pp | 0.00% -0.011 pp | USD— | 8 qtrs SOLD |
| 64 | CRESSET ASSET MANAGEMENT, LLC | — -10.0K (-100.0%) | — -68.3K (-100.0%) | 0.00% -0.020 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
6
Sells
0
Shares acquired
935.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+935,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-30 | Nichols Alexander Julian | Officer | A-Award | A | Stock Option (Right to Buy) | 195,000 | 9.53 | 1.86M | 195,000 | D | ↗ |
| 2026-01-30 | Giguere Lee | Officer | A-Award | A | Stock Option (Right to Buy) | 195,000 | 9.53 | 1.86M | 195,000 | D | ↗ |
| 2026-01-30 | Daws D. Ryan | Officer | A-Award | A | Stock Option (Right to Buy) | 220,000 | 9.53 | 2.10M | 220,000 | D | ↗ |
| 2026-01-30 | Cooper Ronald Harold Wilfred | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 801,000 | 9.53 | 7.63M | 801,000 | D | ↗ |
| 2026-01-30 | Connolly Joan | Officer | A-Award | A | Stock Option (Right to Buy) | 195,000 | 9.53 | 1.86M | 195,000 | D | ↗ |
| 2026-01-30 | CHEUNG ANTHONY TZEYEW | Officer | A-Award | A | Stock Option (Right to Buy) | 195,000 | 9.53 | 1.86M | 195,000 | D | ↗ |
| 2026-01-30 | Buck Jill | Officer | A-Award | A | Stock Option (Right to Buy) | 195,000 | 9.53 | 1.86M | 195,000 | D | ↗ |
| 2026-01-30 | Boyd Matthew Ross | Officer | A-Award | A | Stock Option (Right to Buy) | 195,000 | 9.53 | 1.86M | 195,000 | D | ↗ |
| 2025-09-30 | Sweiti Hussein | Officer | A-Award | A | Stock Option (Right to Buy) | 600,000 | 6.83 | 4.10M | 600,000 | D | ↗ |
| 2025-09-29 | Sweiti Hussein | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-07-08 | Heffernan Michael Thomas | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-07-08 | Grossman William | Director | A-Award | A | Stock Option (Right to Buy) | 45,000 | 3.83 | 172.4K | 45,000 | D | ↗ |
| 2025-07-08 | Buck Jill | Officer | — | — | Stock Option (Right to Buy) | 51,000 | 7.39 | 376.9K | 0 | D | ↗ |
| 2025-07-08 | Boyd Matthew Ross | Officer | — | — | Stock Option (Right to Buy) | 68,000 | 6.60 | 448.8K | 0 | D | ↗ |
| 2025-07-08 | Astley-Sparke Philip | Director | — | — | Common Shares | 0 | 0.00 | — | 20,000 | D | ↗ |
| 2025-06-16 | Zoth Lota S. | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 3.31 | 74.5K | 22,500 | D | ↗ |
| 2025-06-16 | Pott Amy | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 3.31 | 1.32M | 400,000 | D | ↗ |
| 2025-06-16 | Joustra Wouter | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 3.31 | 74.5K | 22,500 | D | ↗ |
| 2025-06-16 | HASTINGS PAUL J | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 3.31 | 74.5K | 22,500 | D | ↗ |
| 2025-06-16 | Glickman Richard M | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 3.31 | 74.5K | 22,500 | D | ↗ |
| 2025-06-16 | Bos Jasper | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 3.31 | 74.5K | 22,500 | D | ↗ |
| 2025-06-16 | BRUNK GERALD A | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 3.31 | 74.5K | 22,500 | D | ↗ |
| 2025-05-27 | Pott Amy | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-01-29 | Pruthi Raj Som | Officer | A-Award | A | Stock Option (Right to Buy) | 280,000 | 7.39 | 2.07M | 280,000 | D | ↗ |
| 2025-01-29 | Nichols Alexander Julian | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 7.39 | 1.85M | 250,000 | D | ↗ |
| 2025-01-29 | Giguere Lee | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 7.39 | 1.85M | 250,000 | D | ↗ |
| 2025-01-29 | Daws D. Ryan | Officer | A-Award | A | Stock Option (Right to Buy) | 280,000 | 7.39 | 2.07M | 280,000 | D | ↗ |
| 2025-01-29 | Cooper Ronald Harold Wilfred | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 850,000 | 7.39 | 6.28M | 850,000 | D | ↗ |
| 2025-01-29 | CHEUNG ANTHONY TZEYEW | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 7.39 | 1.85M | 250,000 | D | ↗ |
| 2024-10-30 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | P-Purchase | A | Common Shares | 561,797 | 8.90 | 5.00M | 3,032,430 | D | ↗ |
| 2024-10-21 | Connolly Joan | Officer | A-Award | A | Stock Option (Right to Buy) | 210,000 | 9.83 | 2.06M | 210,000 | D | ↗ |
| 2024-10-21 | CHEUNG ANTHONY TZEYEW | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 9.83 | 983.0K | 100,000 | D | ↗ |
| 2024-10-08 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | P-Purchase | A | Common Shares | 800 | 6.60 | 5.3K | 2,470,633 | D | ↗ |
| 2024-10-07 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | P-Purchase | A | Common Shares | 11,844 | 6.55 | 77.5K | 2,469,833 | D | ↗ |
| 2024-10-04 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | P-Purchase | A | Common Shares | 5,997 | 6.54 | 39.2K | 2,457,989 | D | ↗ |
| 2024-10-03 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | P-Purchase | A | Common Shares | 5,769 | 6.48 | 37.4K | 2,451,992 | D | ↗ |
| 2024-10-02 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | P-Purchase | A | Common Shares | 10,153 | 6.37 | 64.7K | 2,446,223 | D | ↗ |
| 2024-10-01 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | P-Purchase | A | Common Shares | 35,279 | 6.44 | 227.2K | 2,436,070 | D | ↗ |
| 2024-09-30 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | P-Purchase | A | Common Shares | 341,332 | 6.34 | 2.16M | 2,400,791 | D | ↗ |
| 2024-09-27 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | P-Purchase | A | Common Shares | 38,396 | 5.94 | 228.0K | 2,056,216 | D | ↗ |
| 2024-09-27 | Cooper Ronald Harold Wilfred | Director / Officer | P-Purchase | A | Common Shares | 10,000 | 5.70 | 57.0K | 10,000 | D | ↗ |
| 2023-12-29 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | P-Purchase | A | Common Shares | 9,620 | 9.09 | 87.5K | 2,017,820 | D | ↗ |
| 2023-12-28 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | P-Purchase | A | Common Shares | 5,050 | 7.69 | 38.8K | 2,007,800 | D | ↗ |
| 2023-12-27 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | P-Purchase | A | Common Shares | 2,750 | 7.17 | 19.7K | 2,002,750 | D | ↗ |
| 2023-11-30 | Forbion Capital Fund III Cooperatief U.A. | 10% Owner | — | D | Warrant (Right to Buy) | 475,076 | 11.50 | 5.46M | 0 | — | ↗ |
| 2023-11-30 | FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC | 10% Owner | — | D | Warrants (right to buy) | 446,572 | 0.00 | — | 0 | — | ↗ |
| 2023-11-30 | Daws D. Ryan | Officer | A-Award | A | Stock Option (Right to Buy) | 232,000 | 7.66 | 1.78M | 232,000 | — | ↗ |
| 2023-11-30 | BRYCE RICHARD PAUL | Officer | A-Award | A | Stock Option (Right to Buy) | 153,000 | 7.66 | 1.17M | 153,000 | — | ↗ |
| 2023-11-27 | Daws D. Ryan | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-10-31 | Glickman Richard M | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-10-31 | Forbion Capital Fund III Cooperatief U.A. | 10% Owner | — | D | Class A common shares | 0 | 0.00 | — | 2,894,735 | — | ↗ |
| 2023-10-31 | FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC | 10% Owner | — | D | Common shares | 0 | 0.00 | — | 2,642,110 | — | ↗ |
| 2023-10-31 | BRYCE RICHARD PAUL | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-08-20 | Glickman Richard M | Director | A-Award | A | Stock Option (Right to Buy) | 14,205 | 0.88 | 12.5K | 14,205 | — | ↗ |
| 2020-12-14 | Glickman Richard M | Director | A-Award | A | Stock Option (Right to Buy) | 12,032 | 0.88 | 10.6K | 12,032 | — | ↗ |
| 2018-03-16 | Glickman Richard M | Director | A-Award | A | Stock Option (Right to Buy) | 4,123 | 0.88 | 3.6K | 4,123 | — | ↗ |
| 2017-06-15 | Glickman Richard M | Director | A-Award | A | Stock Option (Right to Buy) | 3,188 | 0.88 | 2.8K | 3,188 | — | ↗ |
| 2016-01-11 | Glickman Richard M | Director | A-Award | A | Stock Option (Right to Buy) | 9,023 | 0.88 | 7.9K | 9,023 | — | ↗ |
| 2015-05-21 | Glickman Richard M | Director | A-Award | A | Stock Option (Right to Buy) | 11,189 | 0.88 | 9.8K | 11,189 | — | ↗ |
| 2013-12-04 | Glickman Richard M | Director | A-Award | A | Stock Option (Right to Buy) | 120 | 0.88 | 105.60 | 120 | — | ↗ |
Executive team
Top executives
Shares Outstanding
51.19M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Ronald H.W. Cooper Chief Executive Officer and President | 700.0K | — | — | 4.54M | 483.0K | 30.5K | 5.76M | 78.93% | ↗ |
| 2 | 2025 | Hussein Sweiti Chief Medical Officer | 43.8K | 212.2K | — | 2.89M | — | 1.6K | 3.15M | 91.83% | ↗ |
| 3 | 2025 | Ryan Daws Chief Financial Officer | 473.0K | — | — | 1.50M | 222.6K | 23.4K | 2.22M | 67.55% | ↗ |
| 4 | 2024 | Ronald H.W. Cooper Chief Executive Officer and President | 197.0K | — | — | 7.99M | 247.0K | 4.5K | 8.43M | 94.68% | ↗ |
| 5 | 2024 | Lee G. Giguere Chief Legal Officer & Secretary | 312.7K | 137.2K | — | 2.70M | 147.9K | 7.7K | 3.30M | 81.67% | ↗ |
| 6 | 2024 | Raj S. Pruthi, MD, MHA, FACS Chief Medical Officer | 253.5K | — | — | 2.01M | 200.3K | 6.3K | 2.47M | 81.34% | ↗ |
| 7 | 2024 | Jason D. Hanson Former Chief Executive Officer | 427.3K | — | — | — | — | 571.9K | 999.3K | 0.00% | ↗ |
| 8 | 2023 | Jason D. Hanson Former Chief Executive Officer | 442.3K | — | — | 1.54M | 204.3K | 9.9K | 2.19M | 70.06% | ↗ |
| 9 | 2023 | Jason D. Hanson Chief Executive Officer | 442.3K | — | — | 1.54M | 204.3K | 9.9K | 2.19M | 70.06% | ↗ |
| 10 | 2023 | Alexander Nichols President and Chief Operating Officer | 312.5K | — | — | 522.1K | 128.3K | 7.0K | 970.0K | 53.82% | ↗ |
| 11 | 2023 | James Sullivan Chief Scientific Officer | 379.5K | — | — | 372.0K | 132.9K | 11.9K | 896.2K | 41.50% | ↗ |
| 12 | 2022 | Jason D. Hanson Chief Executive Officer | 446.4K | — | — | — | 193.6K | 9.2K | 649.2K | 0.00% | ↗ |
| 13 | 2022 | James Sullivan Chief Scientific Officer | 279.3K | — | — | 57.5K | 97.7K | 5.4K | 439.9K | 13.08% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2026-05-08 | DEF 14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ronald H. W. Cooper | President, Chief Executive Officer & Director | 1M | male |
| David Ryan Daws | Chief Financial Officer & Head of Business Development | 719.0K | male |
| Lee G. Giguere | Chief Legal Officer & Corporate Secretary | 605.4K | male |
| Alex Nichols | Chief Strategy & Operations Officer | 504.4K | — |
| Anthony T. Cheung | Co-Founder & Chief Scientific Officer | 341.8K | — |
| Hussein Sweiti | Chief Medical Officer and Head of Research & Development | 257.6K | — |
| Tara Place | Senior Vice President of Human Resources | — | female |
| Amy Pott | Chief Global Commercialization Officer | — | female |
| Jill Buck | Chief Development Officer | — | female |
| Joan Connolly | Chief Technology Officer | — | female |
| Matthew Boyd | Chief Regulatory Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ENGN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
